Highest-materiality recent filing
Perrigo finalizes interim CEO Albert Manzone's compensation: $1.27M salary, $2.5M RSU grant
Albert Manzone appointed Interim President and CEO effective June 7, 2026; fixed term through Dec 31, 2026, with possible 90-day extension.
Perrigo reinstates executive severance policy for transition period around CEO succession
Policy reinstated effective June 29, 2026, covering executive officers except interim CEO and successor CEO.
Perrigo CEO resigns after conduct violation; Board appoints Albert Manzone as interim CEO
Patrick Lockwood-Taylor resigned as President, CEO, and Board member effective June 7, 2026, after Board found personal conduct violated Code of Conduct.
Perrigo Q1 net sales $969M (-7.2%), adj EPS $0.43 (-28%); reaffirms FY 2026 outlook
All In net sales $969M, down 7.2% YoY; reported diluted EPS $(2.81) due to $330.8M goodwill impairment.
Perrigo completes sale of Dermacosmetics business for €305.6M upfront, plus contingent €27M
Upfront cash €305.6M (incl. €5.6M working capital); up to €27M contingent on net sales milestones over three years.
Perrigo revises segment reporting; FY2025 includes $1.36B impairment charge
Self Care segment net sales $2,533.5M in FY2025, down from $2,554.3M in FY2024.
Q4 net sales $1.11B (-2.5% YoY); reported EPS ($10.20) from $1.3B goodwill impairment.
Perrigo Q3 adj EPS $0.80 flat YoY; cuts FY25 guide; starts infant formula review
Q3 net sales $1.04B (-4.1% YoY); adj EPS $0.80 vs $0.81; reported EPS $0.09 vs -$0.13.
Perrigo Q2 2025 Adj EPS $0.57 beats $0.53; net sales $1.06B down 0.9% YoY
Reported EPS $0.00 vs $(0.77); Adj EPS $0.57 up 7.5% YoY on lower interest expense from reduced debt.
Perrigo to sell Dermacosmetics business to KKR for up to €327M
Upfront cash €300M, plus up to €27M milestone payments over three years.
Perrigo restructures leadership; Triona Schmelter departs, Roberto Khoury named EVP & CCO
Triona Schmelter, EVP & President Consumer Self-Care Americas, departs June 30 due to position elimination; remains advisory until Oct 31.
Perrigo Reports Q1 2025 Adjusted EPS Up 106.9% to $0.60, Net Sales $1.04B Down 3.5%
Net sales of $1.04B declined 3.5% due to divestitures and currency; organic net sales down 0.4%.
Perrigo Q4 adj EPS $0.93 (+8.1% YoY); FY 2024 adj EPS $2.57 at guidance midpoint
Q4 net sales $1.14B (-1.6% YoY); organic growth +0.7% despite lost distribution and later cold season.
Perrigo reaches $98M D&O insurance settlement for securities litigation costs
D&O insurers will pay Perrigo $98M inclusive of costs before end of FY2024.
Perrigo Q3 adjusted EPS $0.81 (+26.6% YoY); net sales -3.2% to $1.09B
Adjusted EPS $0.81 vs $0.64 prior year; GAAP EPS loss $(0.13).
Perrigo Q3 adjusted EPS $0.81 (+27% YoY); revenue -3.2%; reaffirms FY outlook
Q3 adjusted EPS $0.81 (+26.6% YoY from $0.64); GAAP EPS ($0.13) vs $0.11 prior year.
Perrigo closes $715M USD and €350M senior notes offering; net proceeds ~$1.076B to refinance debt
Issued $715M 6.125% Senior Notes due 2032 and €350M 5.375% Senior Notes due 2032.
Perrigo Q2 net sales down 10.7% to $1.07B; adjusted EPS $0.53 vs $0.63; lowers FY sales outlook
Q2 net sales $1.07B, down 10.7% YoY; organic sales down 9.1% due to infant formula actions and lower seasonal demand.
Perrigo completes divestiture of HRA Pharma Rare Diseases to Esteve for up to €275M
Total consideration up to €275M: €190M upfront cash plus up to €85M in earnout based on sales milestones.
Perrigo General Counsel Kyle Hanson steps down; Todd Kingma named interim
Kyle Hanson to step down as EVP, General Counsel and Corporate Secretary effective May 30, 2024.
Perrigo Reports Q1 2024 Adjusted EPS of $0.29, Above Projection; Net Sales Down 8.4%
Q1 net sales $1.1B, down 8.4% vs prior year; organic net sales declined 7.0% due to infant formula and SKU prioritization actions.
Perrigo to sell HRA Pharma Rare Diseases to Esteve for up to €275M
Total consideration up to €275M: €190M cash plus up to €85M earnout on sales milestones.
Perrigo Q4 adjusted EPS $0.86 (+14.7%); launches Project Energize
Q4 net sales $1.2B flat YoY; organic net sales -0.6% on SKU cuts and HRA distributor transitions.
Perrigo Q3 adjusted EPS $0.64, revenue $1.1B; lowers FY23 sales guidance
GAAP EPS $0.11 vs -$0.39; adjusted EPS $0.64 vs $0.56, up 14.3% YoY.
Perrigo EVP & President, Consumer Self-Care Americas departs; successor named
James Dillard III mutually separated as EVP & President, Consumer Self-Care Americas effective Sept 11, 2023; advisory role through Sept 30.
Perrigo Q2 adjusted EPS $0.63 beats $0.43 prior year; margins expand 220bps; FY outlook reaffirmed
Q2 net sales $1.2B, +6.4% reported; organic growth 0.8% as SKU prioritization (-2.7pp) and weaker allergy season offset pricing.
Perrigo appoints Patrick Lockwood-Taylor as CEO, effective June 30, 2023; Murray Kessler retires
Patrick Lockwood-Taylor, 54, becomes President, CEO and director, effective June 30, 2023, succeeding Murray Kessler who retires.
Perrigo CEO Murray Kessler to retire July 31, 2023; successor search underway
CEO Murray Kessler to retire effective July 31, 2023, after nearly 5 years leading transformation to consumer self-care.
Perrigo Q1 adj EPS $0.45 (+35.6% YoY); IRS resolves $843M claim; CEO to step down
Net sales $1.2B (+10.0% YoY); organic net sales +6.4%; CSCI segment achieved record sales with constant currency growth of 23.6%.
Perrigo resolves $843M IRS tax dispute; no payment required
IRS fully withdraws proposed $843M in tax adjustments and penalties for Athena's 2011-2013 tax years.
Perrigo Q4 adj EPS $0.75 (+25% YoY); FY net sales $4.5B (+7.6% reported, +12.8% constant currency)
Q4 net sales $1.2B (+4.6% reported, +9.6% constant currency); organic net sales +1.5%.
As previously announced, on June 7, 2026, the Board appointed Albert A. Manzone as the Company’s Interim President and Chief Executive Officer.
On June 30, 2026, the Board of Directors (the “Board”) of Perrigo Company plc (the “Company”) appointed Salman Amin and Omer Gajial to serve as members of the Board effective as of June 30, 2026.
On June 30, 2026, the Board of Directors (the “Board”) of Perrigo Company plc (the “Company”) appointed Salman Amin and Omer Gajial to serve as members of the Board effective as of June 30, 2026.
On June 7, 2026, Patrick Lockwood-Taylor resigned, effective immediately, as President and Chief Executive Officer and as a member of the Board of Directors (the "Board") of Perrigo Company plc (the "Company").
On June 7, 2026, the Board appointed Albert A. Manzone, Director and member of the Audit Committee of the Board, as the Company’s Interim President and Chief Executive Officer.
On June 7, 2026, Patrick Lockwood-Taylor resigned, effective immediately, as President and Chief Executive Officer and as a member of the Board of Directors
Ronald Janish and Perrigo Company plc (“Perrigo” or the “Company”) reached mutual agreement regarding his planned retirement.
On January 29, 2025, Katherine Doyle, an independent member of the Perrigo Company plc (the “Company”) Board of Directors, advised Perrigo’s Nominating & Governance Committee that she will not stand for re-election to our Board of Directors at the Company’s annual general meeting of shareholders in 2025 and intends to retire from our Board at that time.
On January 15, 2025, the Board of Directors of Perrigo Company plc (the “Company” or “Perrigo”) appointed Jonas Samuelson to serve as a member of the Company’s board of directors (the “Board”) effective as of January 15, 2025.
On July 24, 2024, Todd Penegor advised Perrigo Company plc (“Perrigo” or the “Company”) that he would be resigning from the Company’s board of directors (the “Board”), effective July 31, 2024.
appointed Todd Penegor to serve as a member of the Company’s board of directors (the “Board”), to be effective June 21, 2024.
Effective May 30, 2024, Ms. Hanson will step down from her positions as Executive Vice President (“EVP”), General Counsel and Corporate Secretary of the Company and relevant affiliates.
Max materiality 0.90 · Median 0.65 · Most common event leadership